Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T00:46:42.541Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching to amisulpride due to hepatic complications

Published online by Cambridge University Press:  16 April 2020

Oktay Yagdiran ,
Christian Haasen ,
Evangelia Nika ,
Michael Krausz  and
Dieter Naber
Oktay Yagdiran*
Affiliation:
University Hospital Eppendorf, Clinic for Psychiatry and Psychotherapy, Martinistr. 52, 20246Hamburg, Germany
Christian Haasen
Affiliation:
University Hospital Eppendorf, Clinic for Psychiatry and Psychotherapy, Martinistr. 52, 20246Hamburg, Germany
Evangelia Nika
Affiliation:
University Hospital Eppendorf, Clinic for Psychiatry and Psychotherapy, Martinistr. 52, 20246Hamburg, Germany
Michael Krausz
Affiliation:
University Hospital Eppendorf, Clinic for Psychiatry and Psychotherapy, Martinistr. 52, 20246Hamburg, Germany
Dieter Naber
Affiliation:
University Hospital Eppendorf, Clinic for Psychiatry and Psychotherapy, Martinistr. 52, 20246Hamburg, Germany
*
*Corresponding author. Tel.: +49-40-42803-3241; fax: -49-40-42803-9135 E-mail address: yagdiran@uke.uni-hamburg.de (O. Yagdiran).
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Atypical antipsychoticLiver enzyme increaseHepatotoxicityAmisulprideCase report
Type
Case report
Information
European Psychiatry , Volume 17 , Issue 3 , May 2002 , pp. 170 - 171
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS. 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Beasley, CMTollefson, GDTran, PVSafety of olanzapine. J. Clin. Psychiatry 1997;58(Suppl. 10):13–7.Google ScholarPubMed
Coulouvrat, CDondey-Nouvel, LSafety of amisulpride (Soliant): a review of 11 clinical studies. Int. Clin. Psychophar-macol. 1999;14:209–18.CrossRefGoogle Scholar
Dorta, GSiebenmann, RFrohli, PKoelz, HRClozapin-induzierter cholestatischer Ikterus: Ein Fallbericht. Z. Gastro-entrol. 1989;27:388–90.Google Scholar
Gupta, SMansand, PSOlanzapine: review of its pharmacology and indications in clinical practice. Prim. Psychiatry 1997;4: 73–82.Google Scholar
Hummer, MKurz, MKurzthaler, IOberbauer, HMiller, CFleischhacker, WWHepatotoxicity of clozapine. J. Clin. Pharmacol. 1997;17:314–7.Google ScholarPubMed
Lammert, FMatern, SHepatopathien durch Medikamente. Schweiz Rundsch Med. Prax. 1997;86:1167–71.Google Scholar
McEvoy, JPScheifler, PLFrances, AThe expert consensus guideline series: treatment of schizophrenia. J. Clin. Psychiatry 1999;60(Suppl. 11):3–80.Google Scholar
Naber, DLambert, MKrausz, MHaasen, CAtypical Antipsychotics in the Treatment of Schizophrenic Patients. Bremen: Uni-Med; 2001.Google Scholar
Selim, KKaplowitz, NHepatotoxicity of psychotropic drugs. Hepatology 1999;29:1347–51.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.